Ledipasvir
Also known as: Harvoni, Ledifos, Hepcinat LP, Ledviclear (always combined with sofosbuvir)
CAS Number: 1256388-51-8
Antiviral (HCV NS5A Replication Complex Inhibitor)
Pharmacopeia Standards
Mechanism of Action
Ledipasvir is a bridged bis-imidazole NS5A inhibitor that binds domain I of the hepatitis C NS5A protein near the dimer interface. This prevents assembly of functional membrane-associated replication complexes and also impairs virion assembly and release. Potency is highest against genotypes 1, 4, 5 and 6, and it is used only in combination with sofosbuvir to protect against rapid resistance selection.
Technical Specifications
| Generic / INN Name | Ledipasvir |
| CAS Registry Number | 1256388-51-8 |
| Molecular Formula | C49H54F2N8O6 |
| Molecular Weight | 889.00 g/mol g/mol |
| Typical Purity | Not less than 98.0% by HPLC; total impurities NMT 1.5% |
| Storage Conditions | Store at 2 to 8 degrees C or below 25 degrees C per specification, in tightly closed containers with desiccant, protected from light. |
| Shelf Life | 24 to 36 months depending on solid form and packaging configuration |
| Category | Antivirals |
Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.
Typical Applications
Bulk API supplied exclusively for ledipasvir and sofosbuvir fixed-dose combination tablets, including 90 mg adult strengths and reduced paediatric presentations for hepatitis C treatment programmes.
Manufacturers (0+)
View all →Do you manufacture Ledipasvir? Add your free listing and reach global buyers.
Add listing — FreeCan you supply Ledipasvir? List as an authorised distributor or export house.
Register as traderEarn commission by connecting buyers with verified API suppliers. Free to join.
Become an agent